| Year |
Citation |
Score |
| 2023 |
Mukherjee A, Bezwada D, Greco F, Zandbergen M, Shen T, Chiang CY, Tasdemir M, Fahrmann J, Grapov D, La Frano MR, Vu HS, Faubert B, Newman JW, McDonnell LA, Nezi L, ... ... Lengyel E, et al. Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis. Nature Metabolism. PMID 37653041 DOI: 10.1038/s42255-023-00879-8 |
0.414 |
|
| 2023 |
Akasaka H, Lee W, Ko SY, Lengyel E, Naora H. Normal saline remodels the omentum and stimulates its receptivity for transcoelomic metastasis. Jci Insight. 8. PMID 37345662 DOI: 10.1172/jci.insight.167336 |
0.325 |
|
| 2023 |
Shimizu A, Lengyel E. Decoding evolutionary trajectories of ovarian cancer metastasis. Cancer Cell. 41: 1008-1010. PMID 37311411 DOI: 10.1016/j.ccell.2023.05.011 |
0.361 |
|
| 2023 |
Kelliher L, Lengyel E. Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront. Cancer Research. 83: 1383-1385. PMID 37128849 DOI: 10.1158/0008-5472.CAN-23-0333 |
0.37 |
|
| 2023 |
Bajwa P, Kordylewicz K, Bilecz A, Lastra RR, Wroblewski K, Rinkevich Y, Lengyel E, Kenny HA. Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis. Jci Insight. PMID 36795484 DOI: 10.1172/jci.insight.163019 |
0.325 |
|
| 2022 |
Mukherjee A, Bilecz AJ, Lengyel E. The adipocyte microenvironment and cancer. Cancer Metastasis Reviews. PMID 35941408 DOI: 10.1007/s10555-022-10059-x |
0.399 |
|
| 2021 |
Eckert MA, Orozco C, Xiao J, Javellana M, Lengyel E. The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment. Cancers. 13. PMID 34201616 DOI: 10.3390/cancers13133136 |
0.432 |
|
| 2021 |
Cui C, Chakraborty K, Tang XA, Zhou G, Schoenfelt KQ, Becker KM, Hoffman A, Chang YF, Blank A, Reardon CA, Kenny HA, Vaisar T, Lengyel E, Greene G, Becker L. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. PMID 33964209 DOI: 10.1016/j.cell.2021.04.016 |
0.417 |
|
| 2021 |
Javellana M, Eckert M, Stock E, Chapel D, Lastra R, Lengyel E. Neoadjuvant treatment as a window to chemotherapy driven alterations to the genome and transcriptome of high-grade serous ovarian cancer Gynecologic Oncology. 162: S210. DOI: 10.1016/s0090-8258(21)01051-9 |
0.304 |
|
| 2020 |
Alter R, Turaga K, Lengyel E. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer? Jama Network Open. 3: e2014184. PMID 32840618 DOI: 10.1001/jamanetworkopen.2020.14184 |
0.349 |
|
| 2020 |
Mukherjee A, Chiang CY, Daifotis HA, Nieman KM, Fahrmann JF, Lastra RR, Romero IL, Fiehn O, Lengyel E. Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance. Cancer Research. PMID 32054768 DOI: 10.1158/0008-5472.Can-19-1999 |
0.527 |
|
| 2019 |
Hart PC, Kenny HA, Grassl N, Watters KM, Litchfield LM, Coscia F, Blaženović I, Ploetzky L, Fiehn O, Mann M, Lengyel E, Romero IL. Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Reports. 29: 4086-4098.e6. PMID 31851935 DOI: 10.1016/J.Celrep.2019.11.079 |
0.453 |
|
| 2019 |
Kenny HA, Lal-Nag M, Shen M, Kara B, Nahotko DA, Wroblewski K, Fazal S, Chen S, Chiang CY, Chen YJ, Brimacombe KR, Marugan J, Ferrer M, Lengyel E. Quantitative high-throughput screening using an organotypic model identifies compounds that inhibit ovarian cancer metastasis. Molecular Cancer Therapeutics. PMID 31562255 DOI: 10.1158/1535-7163.Mct-19-0052 |
0.416 |
|
| 2019 |
Dauer P, Lengyel E. New Roles for Glycogen in Tumor Progression. Trends in Cancer. 5: 396-399. PMID 31311654 DOI: 10.1016/J.Trecan.2019.05.003 |
0.451 |
|
| 2019 |
Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženović I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, ... ... Lengyel E, et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. PMID 31043742 DOI: 10.1038/S41586-019-1173-8 |
0.498 |
|
| 2019 |
Chryplewicz A, Tienda SM, Nahotko DA, Peters PN, Lengyel E, Eckert MA. Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Scientific Reports. 9: 5195. PMID 30914657 DOI: 10.1038/S41598-019-41352-5 |
0.436 |
|
| 2019 |
Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, ... ... Lengyel ER, et al. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. PMID 30835824 DOI: 10.1002/Cncr.32004 |
0.364 |
|
| 2019 |
Chapel DB, Lengyel E, Ritterhouse LL, Lastra RR. Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. PMID 30807370 DOI: 10.1097/Pgp.0000000000000594 |
0.372 |
|
| 2019 |
McGuire S, Kara B, Hart PC, Montag A, Wroblewski K, Fazal S, Huang XY, Lengyel E, Kenny HA. Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. Gynecologic Oncology. PMID 30797592 DOI: 10.1016/J.Ygyno.2019.01.020 |
0.498 |
|
| 2019 |
Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang CY, Loth R, Lastra R, McGregor SM, Locasale JW, Lengyel E, Romero IL. SPHK1 is a novel target of metformin in ovarian cancer. Molecular Cancer Research : McR. PMID 30655321 DOI: 10.1158/1541-7786.Mcr-18-0409 |
0.516 |
|
| 2019 |
Kenny HA, Lal M, Shen M, Nahotko D, Fazal S, Chen S, Chiang C, Kara B, Yamada SD, Brimacombe K, Marugan J, Ferrer M, Lengyel E. Abstract NT-097: QUANTITATIVE HIGH-THROUGHPUT SCREENING USING AN ORGANOTYPIC MODEL IDENTIFIES TWO KINASE INHIBITORS THAT INHIBIT OVARIAN CANCER METASTASIS Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Nt-097 |
0.474 |
|
| 2019 |
Eckert MA, Coscia F, Chryplewicz AA, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženović I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor S, ... ... Lengyel E, et al. Metabolic reprogramming of the stromal epigenome in ovarian cancer metastasis The Faseb Journal. 33. DOI: 10.1096/fasebj.2019.33.1_supplement.lb240 |
0.358 |
|
| 2019 |
Lazo I, Mukherjee A, Kenny H, Fan S, Blaženović I, Fiehn O, Lengyel E. Profiling the metabolomic composition of the ovarian cancer secretome and ovarian cancer-induced metabolomic changes in mesothelial cells Gynecologic Oncology. 154: 37. DOI: 10.1016/J.Ygyno.2019.04.088 |
0.496 |
|
| 2019 |
Stock E, Lengyel E. Early postoperative increases in platelet count is associated with trend towards improved survival in high grade serous ovarian cancer Gynecologic Oncology. 154. DOI: 10.1016/J.Ygyno.2019.03.203 |
0.405 |
|
| 2018 |
Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. The Journal of Experimental Medicine. PMID 30567719 DOI: 10.1084/Jem.20181170 |
0.529 |
|
| 2018 |
Javellana M, Hoppenot C, Lengyel E. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecologic Oncology. PMID 30471899 DOI: 10.1016/J.Ygyno.2018.11.007 |
0.303 |
|
| 2018 |
Loessner D, Rockstroh A, Shokoohmand A, Holzapfel BM, Wagner F, Baldwin J, Boxberg M, Schmalfeldt B, Lengyel E, Clements JA, Hutmacher DW. A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Biomaterials. 190: 63-75. PMID 30396040 DOI: 10.1016/J.Biomaterials.2018.10.014 |
0.493 |
|
| 2018 |
Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 175: 159-170.e16. PMID 30241606 DOI: 10.1016/J.Cell.2018.08.065 |
0.429 |
|
| 2018 |
Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, ... ... Lengyel E, et al. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metabolism. PMID 30174305 DOI: 10.1016/J.Cmet.2018.08.007 |
0.542 |
|
| 2018 |
Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, Huang JT, Chen SM, Xu ZG, Leng XH, Yu XC, ... ... Lengyel E, et al. mA mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nature Cell Biology. 20: 1074-1083. PMID 30154548 DOI: 10.1038/S41556-018-0174-4 |
0.425 |
|
| 2018 |
Curtis M, Mukherjee A, Lengyel E. The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. Trends in Cancer. 4: 517-519. PMID 30064659 DOI: 10.1016/J.Trecan.2018.06.002 |
0.496 |
|
| 2018 |
Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y. Induction of Neoantigen-specific Cytotoxic T Cells and Construction of T-cell Receptor-engineered T cells for Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29720506 DOI: 10.1158/1078-0432.Ccr-18-0142 |
0.378 |
|
| 2018 |
Lengyel E, Makowski L, DiGiovanni J, Kolonin MG. Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. Trends in Cancer. 4: 374-384. PMID 29709261 DOI: 10.1016/J.Trecan.2018.03.004 |
0.484 |
|
| 2018 |
Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. PMID 29398710 DOI: 10.1038/S41388-017-0093-Z |
0.361 |
|
| 2018 |
Matsuda T, Leisegang M, Park J, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y. Effective screening of neoantigen-specific cytotoxic t cells. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E15061 |
0.366 |
|
| 2018 |
Mukherjee A, Coscia F, Fahrmann J, Chiang C, Smith J, Nieman K, Ladanyi A, Romero I, Fiehn O, Mann M, Lengyel E. Abstract A15: Fatty acid binding protein 4 is indispensable for ovarian cancer metastasis Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Ovca17-A15 |
0.508 |
|
| 2018 |
Hart PC, Chiyoda T, Curtis M, Liu X, Chiang C, McGregor S, Lastra R, Locasale J, Lengyel E, Romero IL. Abstract 5474: Activity of the S1P pathway promotes ovarian cancer and serves as a novel metabolic target of metformin Cancer Research. 78: 5474-5474. DOI: 10.1158/1538-7445.Am2018-5474 |
0.54 |
|
| 2017 |
Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecologic Oncology. PMID 29128106 DOI: 10.1016/J.Ygyno.2017.10.032 |
0.324 |
|
| 2017 |
Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecologic Oncology. PMID 28456378 DOI: 10.1016/J.Ygyno.2017.04.012 |
0.474 |
|
| 2017 |
Lal-Nag M, McGee L, Guha R, Lengyel E, Kenny HA, Ferrer M. A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. Slas Discovery. 2472555216687082. PMID 28346091 DOI: 10.1177/2472555216687082 |
0.417 |
|
| 2017 |
Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL. Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention. Cancer Prevention Research (Philadelphia, Pa.). PMID 28264838 DOI: 10.1158/1940-6207.Capr-16-0281 |
0.483 |
|
| 2017 |
Mukherjee A, Kenny HA, Lengyel E. Unsaturated Fatty Acids Maintain Cancer Cell Stemness. Cell Stem Cell. 20: 291-292. PMID 28257705 DOI: 10.1016/J.Stem.2017.02.008 |
0.374 |
|
| 2017 |
Sundaram KM, Zhang Y, Mitra AK, Kouadio JK, Gwin K, Roman BR, Kossiakoff AA, Lengyel E, Piccirilli J. Prolactin receptor-mediated internalization of imaging agents detects epithelial ovarian cancer with enhanced sensitivity and specificity. Cancer Research. PMID 28202518 DOI: 10.1158/0008-5472.Can-16-1454 |
0.384 |
|
| 2017 |
Eckert MA, Coscia F, Pan S, Chiang C, McGregor S, Lastra R, Yamada SD, Mann M, Lengyel E. Abstract TMEM-118: ROLES OF T-LAK CELL-ORIGINATED KINASE (TOPK) AND THE MICROENVIRONMENT IN DRIVING OVARIAN CANCER PROGRESSION Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Tmem-118 |
0.566 |
|
| 2017 |
Eckert MA, Coscia F, Pan S, Tienda SM, Chryplewicz AA, Chiang C, Montag A, Yamada SD, Mann M, Lengyel ER. Abstract 5899: Compartment-resolved proteomics reveal NNMT as a master metabolic regulator of cancer associated fibroblasts Cancer Research. 77: 5899-5899. DOI: 10.1158/1538-7445.Am2017-5899 |
0.462 |
|
| 2017 |
Hart PC, Sheikh S, Lengyel E, Romero I. Abstract 3062: Metformin inhibits TGFβ-induced stromal ECM remodeling to impede invasion in ovarian cancer Cancer Research. 77: 3062-3062. DOI: 10.1158/1538-7445.Am2017-3062 |
0.556 |
|
| 2016 |
Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discovery. PMID 27856443 DOI: 10.1158/2159-8290.Cd-16-0607 |
0.389 |
|
| 2016 |
Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Morishige KI, Kurachi H, Lengyel E, Kimura T. Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Molecular Cancer Research : McR. PMID 27758876 DOI: 10.1158/1541-7786.Mcr-16-0191 |
0.491 |
|
| 2016 |
Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW. Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metabolism. PMID 27746051 DOI: 10.1016/J.Cmet.2016.09.005 |
0.385 |
|
| 2016 |
Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, Montag A, Lastra RR, Lengyel E, Mann M. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nature Communications. 7: 12645. PMID 27561551 DOI: 10.1038/Ncomms12645 |
0.418 |
|
| 2016 |
Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel E. Reversal of chemoresistance in ovarian cancer by co-delivery of a P-glycoprotein inhibitor and paclitaxel in a liposomal platform. Molecular Cancer Therapeutics. PMID 27466355 DOI: 10.1158/1535-7163.Mct-15-0986 |
0.359 |
|
| 2016 |
Dobbin Z, Cornelison R, Katre AK, Schneider DA, Watters K, Coscia F, Lengyel E, Buechlein A, Fang F, Nephew K, Landen CN. Abstract B39: Identification and targeting mediators of chemoresistance using the patient-derived xenograft model of ovarian cancer Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B39 |
0.473 |
|
| 2016 |
Chiyoda T, Liu X, Lengyel E, Locasale J, Romero I. Abstract A68: Sphingosine kinase 1 as a mediator and predictor of metformin's protective effect in ovarian cancer. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A68 |
0.52 |
|
| 2016 |
Alsaden I, Ross J, Fleming G, Liao C, Johnson A, Lengyel E, Yamada SD. Predictors of Early Recurrence in Advanced Stage, Optimally Debulked Ovarian Cancers Gynecologic Oncology. 143: 211. DOI: 10.1016/J.Ygyno.2016.08.282 |
0.392 |
|
| 2016 |
Fehniger J, Jewell A, Shea K, Lee P, Stewart C, Liao C, Lengyel E, Yamada SD. Ovarian cancer patients treated with intraperitoneal/intravenous chemotherapy do not experience increased toxicity at recurrence Gynecologic Oncology. 141: 192-193. DOI: 10.1016/J.Ygyno.2016.04.497 |
0.427 |
|
| 2015 |
Peters PN, Schryver EM, Lengyel E, Kenny H. Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. Journal of Visualized Experiments : Jove. e53541. PMID 26780294 DOI: 10.3791/53541 |
0.545 |
|
| 2015 |
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, ... ... Lengyel E, et al. Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature. PMID 26503049 DOI: 10.1038/Nature15716 |
0.345 |
|
| 2015 |
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, ... ... Lengyel E, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews. Cancer. 15: 668-79. PMID 26493647 DOI: 10.1038/Nrc4019 |
0.479 |
|
| 2015 |
Litchfield LM, Mukherjee A, Eckert MA, Johnson A, Mills KA, Pan S, Shridhar V, Lengyel E, Romero IL. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. PMID 26172303 DOI: 10.18632/Oncotarget.4556 |
0.461 |
|
| 2015 |
Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecologic Oncology. 138: 656-62. PMID 26115975 DOI: 10.1016/J.Ygyno.2015.06.033 |
0.4 |
|
| 2015 |
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, ... ... Lengyel E, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 521: 489-94. PMID 26017449 DOI: 10.1038/Nature14410 |
0.378 |
|
| 2015 |
Kohlhapp FJ, Mitra AK, Lengyel E, Peter ME. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. PMID 25867073 DOI: 10.1038/Onc.2015.89 |
0.466 |
|
| 2015 |
Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, Lengyel E, Kimura T. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 6: 11342-56. PMID 25839163 DOI: 10.18632/Oncotarget.3604 |
0.433 |
|
| 2015 |
Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecologic Oncology. 137: 485-9. PMID 25838164 DOI: 10.1016/J.Ygyno.2015.03.047 |
0.421 |
|
| 2015 |
Mitra AK, Chiang CY, Tiwari P, Tomar S, Watters KM, Peter ME, Lengyel E. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene. PMID 25798837 DOI: 10.1038/Onc.2015.43 |
0.456 |
|
| 2015 |
Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 680-6. PMID 25691772 DOI: 10.1158/1078-0432.Ccr-14-2198 |
0.486 |
|
| 2015 |
Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, Lengyel E. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nature Communications. 6: 6220. PMID 25653139 DOI: 10.1038/Ncomms7220 |
0.407 |
|
| 2015 |
Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W, Romero IL. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. American Journal of Obstetrics and Gynecology. 212: 479.e1-479.e10. PMID 25446664 DOI: 10.1016/J.Ajog.2014.10.026 |
0.453 |
|
| 2015 |
King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, Montag A, Lengyel E, MacLean Ii JA, Hayashi K. WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 34: 3452-62. PMID 25174399 DOI: 10.1038/Onc.2014.277 |
0.503 |
|
| 2015 |
Zhang Y, Swindell EP, Hankins PL, Kenny HA, O'Halloran TV, Mazar AP, Lengyel E. Abstract POSTER-THER-1440: Targeted delivery of doxorubicin loaded nanobins to ovarian cancer cells through the urokinase plasminogen activator system Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1440 |
0.491 |
|
| 2015 |
Romero IL, Liu X, Mitra AK, Lengyel E, Locasale JW. Abstract POSTER-TECH-1123: Advancing metformin as therapeutic for ovarian cancer: metabolomic profiling of mouse ovarian tumors identifies metformin-induced global metabolic changes Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Tech-1123 |
0.418 |
|
| 2015 |
Zhang Y, Sundaram KM, Li N, Piccirilli JA, Lengyel E. Abstract POSTER-CTRL-1217: Human placental lactogen-functionalized bimodal imaging probe for human ovarian cancer detection Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ctrl-1217 |
0.464 |
|
| 2015 |
Bradaric MJ, Litchfield L, Johnson A, Habis M, Ismail N, Lengyel E, Romero I. Abstract POSTER-BIOL-1305: Lovastatin decreases macrophage IL-6 and CXCL1 production in an ovarian tam-like model reducing ovarian cancer cell invasion Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1305 |
0.54 |
|
| 2015 |
Mitra A, Chiang C, Tiwari P, Peter M, Lengyel E. Abstract AS23: Microenvironment mediated downregulation of miR-193b promotes ovarian cancer metastasis Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-As23 |
0.513 |
|
| 2015 |
Sriraman SK, Zhang Y, Luther E, Lengyel E, Torchilin V. Abstract 4416: Reversal of chemoresistance in ovarian cancer cells by the liposomal co-delivery of MDR inhibitors and paclitaxel Cancer Research. 75: 4416-4416. DOI: 10.1158/1538-7445.Am2015-4416 |
0.442 |
|
| 2015 |
Jewell A, Fehniger J, Stewart C, Lengyel E, Yamada SD. Subsequent chemotherapy is well tolerated in patients who underwent primary adjuvant intraperitoneal chemotherapy for ovarian, fallopian and primary peritoneal cancers Gynecologic Oncology. 139: 203. DOI: 10.1016/J.Ygyno.2015.07.081 |
0.414 |
|
| 2015 |
Mills KA, Becker MA, Febbraro T, Litchfield LM, Lengyel E, Haluska P, Romero I. Advancing metformin as a metabolic therapeutic for ovarian cancer: Testing in non-diabetic patient-derived xenograft avatars Gynecologic Oncology. 137: 63. DOI: 10.1016/J.Ygyno.2015.01.148 |
0.381 |
|
| 2014 |
Febbraro T, Lengyel E, Romero IL. Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecologic Oncology. 135: 614-21. PMID 25455733 DOI: 10.1097/01.Ogx.0000461901.09229.7B |
0.417 |
|
| 2014 |
Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, ... Lengyel E, et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. The Journal of Clinical Investigation. 124: 4614-28. PMID 25202979 DOI: 10.1172/Jci74778 |
0.468 |
|
| 2014 |
Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero IL. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. Plos One. 9: e104521. PMID 25118694 DOI: 10.1371/Journal.Pone.0104521 |
0.335 |
|
| 2014 |
White EA, Kenny HA, Lengyel E. Three-dimensional modeling of ovarian cancer. Advanced Drug Delivery Reviews. 79: 184-92. PMID 25034878 DOI: 10.1016/J.Addr.2014.07.003 |
0.496 |
|
| 2014 |
Ko SY, Ladanyi A, Lengyel E, Naora H. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. The American Journal of Pathology. 184: 271-81. PMID 24332016 DOI: 10.1016/J.Ajpath.2013.09.017 |
0.496 |
|
| 2014 |
Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS. Epithelial ovarian cancer experimental models. Oncogene. 33: 3619-33. PMID 23934194 DOI: 10.1038/Onc.2013.321 |
0.429 |
|
| 2014 |
Jewell A, Watters K, Mitra AK, Bao R, Chiang CY, Curtis M, Andrade J, Yamada DS, Lengyel E. MicroRNA 206 is associated with longer overall survival and platinum sensitivity in serous epithelial ovarian cancer Gynecologic Oncology. 133: 18. DOI: 10.1016/J.Ygyno.2014.03.064 |
0.461 |
|
| 2013 |
Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O'Halloran TV, Lengyel E. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Molecular Cancer Therapeutics. 12: 2628-39. PMID 24061648 DOI: 10.1158/1535-7163.Mct-13-0204 |
0.521 |
|
| 2013 |
Landen CN, Lengyel E. Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. Gynecologic Oncology. 130: 6-8. PMID 23926600 DOI: 10.1016/J.Ygyno.2013.05.031 |
0.386 |
|
| 2013 |
Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochimica Et Biophysica Acta. 1831: 1533-41. PMID 23500888 DOI: 10.1016/J.Bbalip.2013.02.010 |
0.504 |
|
| 2013 |
Ohyagi-Hara C, Sawada K, Kamiura S, Tomita Y, Isobe A, Hashimoto K, Kinose Y, Mabuchi S, Hisamatsu T, Takahashi T, Kumasawa K, Nagata S, Morishige K, Lengyel E, Kurachi H, et al. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin α5 expression. The American Journal of Pathology. 182: 1876-89. PMID 23499550 DOI: 10.1016/J.Ajpath.2013.01.039 |
0.411 |
|
| 2013 |
Lengyel E, Fleming S, McEwen KA, Montag A, Temkin SM. Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecologic Oncology. 129: 120-3. PMID 23237768 DOI: 10.1016/J.Ygyno.2012.12.006 |
0.314 |
|
| 2013 |
Nieman K, Ladanyi A, Lengyel E. Abstract IA30: Metabolic symbiosis: The contribution of adipocytes to visceral metastasis Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-Ia30 |
0.485 |
|
| 2013 |
Ko SY, Barengo N, Ladanyi A, Lee J, Marini F, Lengyel E, Naora H. Abstract 2611: The developmental patterning geneHOXA9promotes ovarian cancer growth via paracrine effects on mesenchymal stem cells and peritoneal fibroblasts. Cancer Research. 73: 2611-2611. DOI: 10.1158/1538-7445.Am2013-2611 |
0.494 |
|
| 2013 |
Ladanyi A, Nieman K, Penicka C, Mitra A, Kenny H, Gwin K, Wolsky R, Yamada SD, Lengyel E. Abstract 1870: Omental adipocytes promote overexpression of CD36 in ovarian cancer cells and enhance tumorigenicity. Cancer Research. 73: 1870-1870. DOI: 10.1158/1538-7445.Am2013-1870 |
0.441 |
|
| 2013 |
Kenny HA, Chiang C, Ladanyi A, George J, Bowtell DD, Gwin K, Mazar A, Lengyel E. Abstract PR11: Ovarian cancer cells activate the mesothelium in the peritoneal microenvironment promoting fibronectin production and the early steps of metastasis Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-Pr11 |
0.507 |
|
| 2013 |
Stringer EM, Skor MN, Zhao L, Gwin K, Lengyel E, Fleming GF, Conzen SD. Abstract B32: The role of the glucocorticoid receptor (GR) in inhibiting chemotherapy-induced apoptosis in high-grade serous ovarian carcinoma (HGS-OvCa) Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B32 |
0.469 |
|
| 2013 |
Lengyel E, Tiwari P, Chiang C, Zhang Y, Mitra A. Regulation of ovarian cancer metastatic colonization by MIR-193B Gynecologic Oncology. 131: 259-260. DOI: 10.1016/J.Ygyno.2013.07.033 |
0.399 |
|
| 2013 |
Jewell AD, Mitra AK, Chiang C, Yamada SD, Lengyel E. Identifying the microrna expression signature associated with chemoresistance in ovarian cancer Gynecologic Oncology. 131: 256-257. DOI: 10.1016/J.Ygyno.2013.07.025 |
0.488 |
|
| 2012 |
Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discovery. 2: 1100-8. PMID 23171795 DOI: 10.1158/2159-8290.Cd-12-0206 |
0.778 |
|
| 2012 |
Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. The Journal of Clinical Investigation. 122: 3603-17. PMID 22945634 DOI: 10.1172/Jci62229 |
0.479 |
|
| 2012 |
Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SD. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecologic Oncology. 127: 316-20. PMID 22835717 DOI: 10.1016/J.Ygyno.2012.07.105 |
0.402 |
|
| 2012 |
Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstetrics and Gynecology. 119: 61-7. PMID 22183212 DOI: 10.1097/AOG.0b013e3182393ab3 |
0.363 |
|
| 2012 |
Romero IL, Lee W, Mitra AK, Gordon IO, Zhao Y, Leonhardt P, Penicka CV, Mui KL, Krausz TN, Greene GL, Lengyel E. The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis Gynecologic Oncology. 124: 134-141. PMID 21996264 DOI: 10.1016/J.Ygyno.2011.08.026 |
0.356 |
|
| 2012 |
Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, Hua YJ, Lengyel E, Peter ME. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. International Journal of Cancer. 130: 1787-97. PMID 21618519 DOI: 10.1002/Ijc.26190 |
0.792 |
|
| 2012 |
Kenny HA, Nieman KM, Penicka C, Leonhardt P, Ladanyi A, Mazar AP, Gwin K, Lengyel E. Abstract 5185: Ovarian cancer cells induce fibronectin production in the peritoneal microenvironment through a TGFβRI-dependent mechanism which promotes the early steps of metastasis Cancer Research. 72: 5185-5185. DOI: 10.1158/1538-7445.Am2012-5185 |
0.515 |
|
| 2012 |
Zillhardt M, Lengyel E. Abstract 48: Activation of c-Met receptor signaling by carcinoma-associated fibroblasts in the tumor microenvironment Cancer Research. 72: 48-48. DOI: 10.1158/1538-7445.Am2012-48 |
0.819 |
|
| 2012 |
Zhang Y, Swindell EP, Ahn RW, Mitra A, Mazar AP, O'Halloran TV, Kenny HA, Lengyel E. Abstract 2885: Urokinase plasminogen activator system targeted delivery of arsenic trioxide loaded nanobins as a novel ovarian cancer therapeutic Cancer Research. 72: 2885-2885. DOI: 10.1158/1538-7445.Am2012-2885 |
0.526 |
|
| 2012 |
Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E. Abstract 1481: microRNA mediated reprograming of fibroblasts into cancer associated fibroblasts in ovarian cancer Cancer Research. 72: 1481-1481. DOI: 10.1158/1538-7445.Am2012-1481 |
0.817 |
|
| 2012 |
Hunn J, Tenney M, Bishop E, Moore K, Tergas A, Lengyel E, Lee N, Yamada S. Utility of routine surveillance methods in detecting recurrence in high grade endometrial cancer patients Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.372 |
0.409 |
|
| 2012 |
Romero I, Bradaric M, Lee W, Penicka C, Mitra A, Lengyel E. Metformin: A novel agent for ovarian cancer prevention and adjuvant treatment Gynecologic Oncology. 125: S100. DOI: 10.1016/J.Ygyno.2011.12.240 |
0.44 |
|
| 2011 |
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Medicine. 17: 1498-503. PMID 22037646 DOI: 10.1038/Nm.2492 |
0.822 |
|
| 2011 |
Kenny HA, Nieman KM, Mitra AK, Lengyel E. The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discovery. 1: 100-2. PMID 22013555 DOI: 10.1158/2159-8290.Cd-11-0117 |
0.396 |
|
| 2011 |
Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews. Cancer. 11: 719-25. PMID 21941283 DOI: 10.1038/Nrc3144 |
0.432 |
|
| 2011 |
Buell-Gutbrod R, Ivanovic M, Montag A, Lengyel E, Fadare O, Gwin K. FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 14: 391-5. PMID 21682576 DOI: 10.2350/10-12-0943-Oa.1 |
0.324 |
|
| 2011 |
Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4042-51. PMID 21551255 DOI: 10.1158/1078-0432.Ccr-10-3387 |
0.806 |
|
| 2011 |
Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecologic Oncology. 121: 273-9. PMID 21276608 DOI: 10.1016/J.Ygyno.2010.12.362 |
0.371 |
|
| 2011 |
Bishop EA, Lengyel ER, Yamada SD, Montag A, Temkin SM. The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecologic Oncology. 121: 218-23. PMID 21168200 DOI: 10.1016/j.ygyno.2010.11.031 |
0.338 |
|
| 2011 |
Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis Clinical Cancer Research. 17: 459-471. PMID 21149615 DOI: 10.1158/1078-0432.Ccr-10-2258 |
0.455 |
|
| 2011 |
Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 30: 1566-76. PMID 21119598 DOI: 10.1038/Onc.2010.532 |
0.405 |
|
| 2011 |
Ohyagi C, Sawada K, Morishige K, Lengyel E, Kimura T. Abstract 1544: Identification of microRNA which regulates peritoneal dissemination of ovarian cancer Cancer Research. 71: 1544-1544. DOI: 10.1158/1538-7445.Am2011-1544 |
0.436 |
|
| 2011 |
Goldberg MB, Dorn P, Lengyel E, Lee NK, Yamada D, Hasan Y. Locoregional Failure In High-risk Endometrial Cancer And The Role Of Whole Pelvis External Beam RT International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.758 |
0.328 |
|
| 2010 |
Lengyel E. Ovarian cancer development and metastasis. The American Journal of Pathology. 177: 1053-64. PMID 20651229 DOI: 10.2353/Ajpath.2010.100105 |
0.489 |
|
| 2010 |
Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME. CD95 promotes tumour growth. Nature. 465: 492-6. PMID 20505730 DOI: 10.1038/Nature09075 |
0.375 |
|
| 2010 |
Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia (New York, N.Y.). 12: 1-10. PMID 20072648 DOI: 10.1593/Neo.09948 |
0.809 |
|
| 2010 |
Ko SY, Lengyel E, Naora H. The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. Molecular and Cellular Endocrinology. 317: 112-9. PMID 20036708 DOI: 10.1016/J.Mce.2009.12.025 |
0.478 |
|
| 2010 |
Banz C, Ungethuem U, Kuban RJ, Diedrich K, Lengyel E, Hornung D. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertility and Sterility. 94: 1212-7. PMID 19643405 DOI: 10.1016/J.Fertnstert.2009.06.039 |
0.491 |
|
| 2010 |
Romero IL, Lee W, Mui K, Leonhardt P, Penicka C, Greene GL, Lengyel E. Abstract A103: The effect of 17β-estradiol on ovarian carcinogenesis in vitro and in a genetic mouse model Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-A103 |
0.483 |
|
| 2010 |
Chen L, Park S, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu Y, Romero I, Lengyel E, Peter ME. Abstract LB-341: CD95/FAS promotes tumorigenesis Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-341 |
0.413 |
|
| 2010 |
Kenny HA, Leonhardt P, Ladanyi A, Gwin K, Lengyel E. Abstract 2331: One of the first steps of metastasis is remodeling of the extracellular matrix microenvironment Cancer Research. 70: 2331-2331. DOI: 10.1158/1538-7445.Am10-2331 |
0.477 |
|
| 2009 |
Vergote IB, Colombo N, Kutarska E, Del Campo J, Pippitt C, Casado A, Lengyel E, Gilder K, Ho S, Schilder RJ. Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5560. PMID 27962571 DOI: 10.1200/Jco.2009.27.15_Suppl.5560 |
0.402 |
|
| 2009 |
Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK, Lengyel E. {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. The American Journal of Pathology. 175: 2184-96. PMID 19808644 DOI: 10.2353/Ajpath.2009.090028 |
0.781 |
|
| 2009 |
Kenny HA, Dogan S, Zillhardt M, K Mitra A, Yamada SD, Krausz T, Lengyel E. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treatment and Research. 149: 335-51. PMID 19763444 DOI: 10.1007/978-0-387-98094-2_16 |
0.78 |
|
| 2009 |
Romero IL, Gordon IO, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu DM, Krausz TN, Kim HH, Gilliam ML, Lengyel E. Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prevention Research (Philadelphia, Pa.). 2: 792-9. PMID 19737983 DOI: 10.1097/01.Ogx.0000367518.33665.Ea |
0.377 |
|
| 2009 |
Arimoto-Ishida E, Sakata M, Sawada K, Nakayama M, Nishimoto F, Mabuchi S, Takeda T, Yamamoto T, Isobe A, Okamoto Y, Lengyel E, Suehara N, Morishige K, Kimura T. Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation. Endocrinology. 150: 4306-15. PMID 19497979 DOI: 10.1210/En.2008-1662 |
0.32 |
|
| 2009 |
Kenny HA, Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle (Georgetown, Tex.). 8: 683-8. PMID 19221481 DOI: 10.4161/Cc.8.5.7703 |
0.459 |
|
| 2009 |
Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, ... Lengyel E, et al. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. 17: 57-67. PMID 18815565 DOI: 10.1097/Pai.0B013E3181816Ae2 |
0.397 |
|
| 2008 |
Lindemann K, Harbeck N, Lengyel E, Resau JH. A special key for unlocking the door to targeted therapies of breast cancer. Thescientificworldjournal. 8: 905-8. PMID 18836657 DOI: 10.1100/Tsw.2008.110 |
0.419 |
|
| 2008 |
Terplan M, Temkin S, Tergas A, Lengyel E. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecologic Oncology. 111: 173-8. PMID 18823649 DOI: 10.1016/J.Ygyno.2008.08.013 |
0.434 |
|
| 2008 |
Onujiogu N, Lengyel E, Yamada SD. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer Gynecologic Oncology. 111: 537-539. PMID 18554701 DOI: 10.1016/J.Ygyno.2008.04.032 |
0.346 |
|
| 2008 |
Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes & Development. 22: 894-907. PMID 18381893 DOI: 10.1101/Gad.1640608 |
0.414 |
|
| 2008 |
Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel E. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Research. 68: 2329-39. PMID 18381440 DOI: 10.1158/0008-5472.Can-07-5167 |
0.479 |
|
| 2008 |
Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. The Journal of Clinical Investigation. 118: 1367-79. PMID 18340378 DOI: 10.1172/Jci33775 |
0.393 |
|
| 2008 |
Radjabi AR, Sawada K, Jagadeeswaran S, Eichbichler A, Kenny HA, Montag A, Bruno K, Lengyel E. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. The Journal of Biological Chemistry. 283: 2822-34. PMID 18048360 DOI: 10.1074/Jbc.M704855200 |
0.348 |
|
| 2008 |
Temkin SM, Lengyel E, Tergas A, Terplan M. Ovarian cancer treatment in black and white women: A comparison of clinico-pathologic factors and outcome Journal of Clinical Oncology. 26: 16531-16531. DOI: 10.1200/Jco.2008.26.15_Suppl.16531 |
0.367 |
|
| 2008 |
Matthews C, Ho S, Barve M, Bell-McGuinn K, Gilbert L, Penson R, Lengyel E, Weymer S, Gilder K, Schilder R. 519 POSTER A phase 2, single-arm study of volociximab (an anti-a5b1 integrin antibody) monotherapy in patients with platinum-resistant advanced epithelial ovarian cancer or primary peritoneal cancer European Journal of Cancer Supplements. 6: 164-165. DOI: 10.1016/S1359-6349(08)72453-4 |
0.442 |
|
| 2007 |
Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2 Cell Cycle. 6: 2585-2590. PMID 17957144 DOI: 10.4161/Cc.6.21.4845 |
0.456 |
|
| 2007 |
Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, Peter ME. Let-7 expression defines two differentiation stages of cancer Proceedings of the National Academy of Sciences of the United States of America. 104: 11400-11405. PMID 17600087 DOI: 10.1073/Pnas.0704372104 |
0.452 |
|
| 2007 |
Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 51: 54-62. PMID 17593080 DOI: 10.1111/J.1365-2559.2007.02732.X |
0.332 |
|
| 2007 |
Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. International Journal of Cancer. 121: 1463-72. PMID 17546601 DOI: 10.1002/Ijc.22874 |
0.52 |
|
| 2007 |
Leupold JH, Asangani I, Maurer GD, Lengyel E, Post S, Allgayer H. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. Molecular Cancer Research : McR. 5: 485-96. PMID 17510314 DOI: 10.1158/1541-7786.Mcr-06-0211 |
0.448 |
|
| 2007 |
Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Current Molecular Medicine. 7: 77-84. PMID 17311534 DOI: 10.2174/156652407779940486 |
0.327 |
|
| 2007 |
Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Research. 67: 1670-9. PMID 17308108 DOI: 10.1158/0008-5472.Can-06-1147 |
0.493 |
|
| 2007 |
Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD. PDGFR-α as a potential therapeutic target in uterine sarcomas Gynecologic Oncology. 104: 524-528. PMID 17049587 DOI: 10.1016/J.Ygyno.2006.09.013 |
0.331 |
|
| 2006 |
Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 66: 1356-65. PMID 16757127 DOI: 10.1016/J.Ijrobp.2006.03.018 |
0.31 |
|
| 2005 |
Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. International Journal of Cancer. Journal International Du Cancer. 113: 678-82. PMID 15455388 DOI: 10.1002/Ijc.20598 |
0.392 |
|
| 2004 |
Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene. 23: 9369-80. PMID 15516977 DOI: 10.1038/Sj.Onc.1208182 |
0.322 |
|
| 2001 |
Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecologic Oncology. 82: 291-8. PMID 11531282 DOI: 10.1006/Gyno.2001.6243 |
0.386 |
|
| 2001 |
Lengyel E, Ried S, Heiss MM, Jäger C, Schmitt M, Allgayer H. Ras regulation of urokinase-type plasminogen activator. Methods in Enzymology. 333: 105-116. PMID 11400328 DOI: 10.1016/S0076-6879(01)33049-5 |
0.368 |
|
| 2001 |
Hapke S, Kessler H, Prada NAd, Benge A, Schmitt M, Lengyel E, Reuning U. Integrin αvβ3/Vitronectin Interaction Affects Expression of the Urokinase System in Human Ovarian Cancer Cells Journal of Biological Chemistry. 276: 26340-26348. PMID 11331280 DOI: 10.1074/Jbc.M100181200 |
0.466 |
|
| 2001 |
Allgayer H, Schewe D, Boyd DD, Lengyel E, Wang H, Gruetzner U, Schildberg FW, Heiss M. First clinical evidence of a combined AP-2/Sp1 promoter motif as a tumor-specific activator of urokinase-receptor (u-PAR) expression in resected gastrointestinal cancers European Journal of Cancer. 37. DOI: 10.1016/S0959-8049(01)80457-3 |
0.416 |
|
| 2000 |
Muehlenweg B, Schnelzer A, Türkmen B, Lengyel E, Reuning U, Graeff H, Schmitt M, Magdolen V. RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. Methods in Molecular Medicine. 39: 299-306. PMID 21340784 DOI: 10.1385/1-59259-071-3:299 |
0.401 |
|
| 2000 |
Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 19: 3013-3020. PMID 10871853 DOI: 10.1038/Sj.Onc.1203621 |
0.353 |
|
| 2000 |
Schmitt M, Wilhelm OG, Reuning U, Krüger A, Harbeck N, Lengyel E, Graeff H, Gänsbacher B, Kessler H, Bürgle M, Stürzebecher J, Sperl S, Magdolen V. The urokinase plasminogen activator system as a novel target for tumour therapy Fibrinolysis and Proteolysis. 14: 114-132. DOI: 10.1054/Fipr.2000.0079 |
0.407 |
|
| 1999 |
Ried S, Jäger C, Jeffers M, Woude GFV, Graeff H, Schmitt M, Lengyel E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. Journal of Biological Chemistry. 274: 16377-16386. PMID 10347197 DOI: 10.1074/Jbc.274.23.16377 |
0.361 |
|
| 1997 |
Lengyel E, Wang H, Gum R, Simon C, Wang Y, Boyd D. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade Oncogene. 14: 2563-2573. PMID 9191056 DOI: 10.1038/Sj.Onc.1201098 |
0.397 |
|
| 1997 |
Gum R, Wang H, Lengyel E, Juarez J, Boyd D. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades Oncogene. 14: 1481-1493. PMID 9136992 DOI: 10.1038/Sj.Onc.1200973 |
0.323 |
|
| 1996 |
Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, Doe W, Pfarr CM, Boyd D. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. The Journal of Biological Chemistry. 271: 23176-84. PMID 8798512 DOI: 10.1074/Jbc.271.38.23176 |
0.344 |
|
| 1996 |
Lengyel E, Gum R, Stepp E, Juarez J, Wang H, Boyd DD. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line Journal of Cellular Biochemistry. 61: 430-443. PMID 8761947 DOI: 10.1002/(Sici)1097-4644(19960601)61:3<430::Aid-Jcb10>3.0.Co;2-N |
0.317 |
|
| 1995 |
Schaller G, Fuchs I, Pritze W, Ebert A, Kratzsch HC, weitzel H, Herbst H, Lengyel E. 677 The clinical importance of keratin 18 in breast cancer European Journal of Cancer. 31. DOI: 10.1016/0959-8049(95)95927-X |
0.31 |
|
| Show low-probability matches. |